newsfilter
← Latest News
GlobeNewswire·

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing